AREV Nanotec Appoints Chad S. Johnson, Esq. as Special Counsel for Corporate Development


VANCOUVER, BC – TheNewswire - March 1, 2021 - AREV NANOTEC BRANDS INC. (CSE:AREV) (CNSX:AREV.CN) (OTC:AREVF) (“AREV Nanotec” or “AREV”) is pleased to announce that the Company has appointed Chad S. Johnson, Esq., as Special Counsel for Corporate Development.

Complementing AREV’s announced corporate and development activities, Mr. Johnson and his staff will serve AREV in a variety of capacities, including media strategy development, government affairs and legislative advocacy, facilitation of scientific advisory appointments, coordination of trade organization memberships, organization of global scientific conference operations, and management of relationships with clinical societies and academies.  Mr. Johnson will also assist in developing collaborations with academic research institutions and private sector partners to accelerate AREV’s pre-clinical drug discovery platform.


Mike Withrow, CEO of AREV Nanotec, stated, “Mr. Johnson has extensive experience working within the early-stage life sciences industry and has created significant value for multiple biotechnology start-ups in his career.  Chad’s broad advocacy experience with non-profit organizations addressing HIV and other pandemic infectious diseases positions him to advance AREV in its corporate pivot as a life science entity, following the initiation of the Company’s clinical human nutrition development program and preclinical phytomedicinal anti-viral discovery program.”

Mr. Johnson, a graduate of Harvard Law School, is an active member of the District of Columbia Bar and the Bar of the U.S. Supreme Court.  Mr. Johnson has served as an executive officer, board member, or counsel for several for-profit and not-for-profit organizations in North America and Europe.  He is a member of the International AIDS Society (IAS), NMAC, and the Infectious Disease Society of America (IDSA).  Mr. Johnson has attended numerous scientific conferences internationally, including the IAS, the European Congress of Clinical Microbiology & Infectious Diseases (EECMID), the U.S Conference on AIDS, the IAS Conference on HIV Science, the International Symposium on HIV and Emerging Infectious Diseases (ISHEID), and the National HIV Prevention Conference (NHPC) of the U.S. Centers for Disease Control and Prevention (CDC), among others.  Mr. Johnson participates in AIDSWatch, the largest national advocacy effort in the United States for AIDS treatment and research.

Chad Johnson stated, “AREV is well positioned to advance its research and product development over the next three quarters through the establishment of several strategic collaborations and partnerships, and I greatly look forward to working with the growing team of life science experts at AREV to further progress the Company’s life-saving innovations.”

For further information, contact Mike Withrow, 778-929-6536. For more information visit

On behalf of the Board,

Mike Withrow
CEO & Director

About AREV NanoTec Brands Inc.  
AREV NanoTec Brands Inc. (CSE: AREV) (OTC: AREVF) produces phytomedicinal extracts via its proprietary state-of-the-art extraction methodologies for the life science industry. These premium ingredients are utilized in SUS-TAINN™, a Ready-To-Use Therapeutic Food (RUTF) to impact global malnutrition on Severe / Acute Malnutrition (SAM) and the Enteral Formula markets. The AREV model is to advance extraction technologies that provide opportunities for next generation phytomedicine.  AREV Nanotec is a member of BIO, the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other countries.



Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements.  Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on   

Copyright (c) 2021 TheNewswire - All rights reserved.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.